Two randomized open-label studies of daratumumab (DARA) plus standard of care treatment versus standard of care alone in patients with previously untreated multiple myeloma (MM) ineligible for high-dose therapy: 54767414MMY3007 (Alcyone) and 54767414MMY3008 (Maia)
| Autor: | Facon, T., Cavo, M., Jakubowiak, A., San Miguel, J., Kumar, S., Orlowski, R.Z., Usmani, S., Palumbo, A., Bandekar, R., Wang, J., Crist, W., O’Rourke, L., Carson, R., Wu, K., Qi, M., Ahmadi, T., Mateos, M.V. |
|---|---|
| Zdroj: | In Clinical Lymphoma Myeloma and Leukemia September 2015 15 Supplement 3:e294-e295 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect